

Sergey Menis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10801921/publications.pdf>

Version: 2024-02-01

37
papers

5,496
citations

172457

29
h-index

361022

35
g-index

39
all docs

39
docs citations

39
times ranked

4794
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. <i>Science</i> , 2013, 340, 711-716.	12.6	680
2	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012, 490, 417-420.	27.8	405
3	Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. <i>Science</i> , 2015, 349, 156-161.	12.6	358
4	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	14.3	335
5	Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. <i>Cell</i> , 2019, 177, 1153-1171.e28.	28.9	293
6	Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 655-663.	8.5	275
7	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. <i>Immunity</i> , 2018, 48, 133-146.e6.	14.3	274
8	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016, 166, 1459-1470.e11.	28.9	230
9	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. <i>Science</i> , 2019, 363, 649-654.	12.6	227
10	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016, 16, 2327-2338.	6.4	216
11	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016, 166, 1471-1484.e18.	28.9	198
12	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. <i>Nature Communications</i> , 2017, 8, 14954.	12.8	176
13	Engineered immunogen binding to alum adjuvant enhances humoral immunity. <i>Nature Medicine</i> , 2020, 26, 430-440.	30.7	172
14	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. <i>Science Translational Medicine</i> , 2014, 6, 236ra63.	12.4	160
15	Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. <i>Immunity</i> , 2020, 53, 548-563.e8.	14.3	149
16	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. <i>Science</i> , 2016, 353, 1557-1560.	12.6	147
17	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015, 11, e1004932.	4.7	141
18	Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16473-16478.	7.1	141

#	ARTICLE	IF	CITATIONS
19	Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. <i>Nature Communications</i> , 2018, 9, 3693.	12.8	124
20	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. <i>Nature Communications</i> , 2015, 6, 7479.	12.8	113
21	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	113
22	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. <i>Immunity</i> , 2018, 49, 301-311.e5.	14.3	110
23	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. <i>Immunity</i> , 2019, 51, 141-154.e6.	14.3	71
24	Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. <i>Scientific Reports</i> , 2018, 8, 16527.	3.3	69
25	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. <i>Molecular Therapy</i> , 2019, 27, 2080-2090.	8.2	58
26	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	3.2	51
27	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22920-22931.	7.1	42
28	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. <i>Npj Vaccines</i> , 2020, 5, 72.	6.0	39
29	Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. <i>Virology</i> , 2017, 505, 193-209.	2.4	36
30	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. <i>Advanced Science</i> , 2020, 7, 1902802.	11.2	30
31	Glycoengineering HIV-1 Env creates "supercharged" and "hybrid" glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018, 14, e1007024.	4.7	22
32	Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. <i>Biomaterials</i> , 2021, 275, 120868.	11.4	16
33	A Chimeric HIV-1 Envelope Glycoprotein Trimer with an Embedded Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Domain Induces Enhanced Antibody and T Cell Responses. <i>Journal of Biological Chemistry</i> , 2011, 286, 22250-22261.	3.4	15
34	An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells. <i>PLoS ONE</i> , 2013, 8, e67309.	2.5	4
35	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) <i>Tj ETQq1 11.0.7843 14 rgBT / Ov</i>		
36	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A25-A26.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Investigating Epitope Exposure on Native Trimers. AIDS Research and Human Retroviruses, 2014, 30, A35-A35.	1.1	0